FDA Approves First KRAS Inhibitor: Sotorasib
Unknown authors
Abstract
The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase II trial, the drug yielded a median progression-free survival of 6.8 months in patients whose disease had advanced despite treatment with standard therapies, namely platinum-based chemotherapy and PD-1-PD-L1 inhibitors.
Topics & Concepts
MedicineKRASChemotherapyDrugLung cancerOncologyCancerDiseaseInternal medicineCancer researchFood and drug administrationDrug approvalApproved drugPhases of clinical researchClinical trialDrug repositioningTargeted therapyCancer drugsStandard of careLungMalignant diseaseAnticancer drugOverall survivalLung Cancer Treatments and MutationsMelanoma and MAPK PathwaysInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis